SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

PDS0301

PDSB·PDS Biotechnology Corp
MIXED
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
Why 4/10
PDS0301 is a Phase 2 asset with no hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The next company-level catalyst is Q3 2026 earnings on November 12, 2026, but that is a financial update, not a drug-specific binary. The drug is now the company's sole internally-funded asset following the August 2026 strategic refocus, but its mid-stage status limits the near-term share-price impact potential.
Actionable Insight MIXED

PDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

Price Chart

Loading chart...

Executive Summary

PDS0301 (also known as PDS01ADC) is a tumor-targeted immunocytokine (IL-12 antibody fusion) being developed by PDS Biotechnology Corp (Nasdaq: PDSB) for metastatic colorectal cancer (mCRC) with liver metastases. In August 2026, the company made PDS0301 its sole internally-funded asset, discontinuing its Phase 3 PDS0101 head-and-neck cancer program after Phase 2 data showed a 71% overall response rate in mCRC patients with liver metastases. The stock crashed roughly 67% on the news. A subsequent $22.3M PIPE financing led by Dr. Patrick Soon-Shiong's Nant Capital in September 2026 provided capital and board-level strategic support. PDS0301 is still in Phase 2 development with no hard dated binary catalyst (PDUFA or pivotal readout) scheduled in the next 12 months. The stock trades near $1.03 with a mean analyst price target of $4.50, reflecting strong bullish sentiment from covering analysts, but the single-asset, pre-revenue profile carries high execution and financing risk.

How It Works

PDS0301 (also called PDS01ADC) is a tumor-targeted immunocytokine, a type of antibody-drug conjugate. It fuses a tumor-targeting antibody to interleukin-12 (IL-12), a potent immune-signaling protein. The antibody portion homes in on the tumor, delivering IL-12 directly into the cancer microenvironment. This stimulates the patient's own immune T cells and natural killer cells to attack the tumor while limiting the systemic side effects that free IL-12 would cause. In plain terms, it is a guided missile that delivers an immune-boosting payload straight to the cancer.

Trial Status

PDS0301 has generated Phase 2 data in metastatic colorectal cancer (mCRC) with liver metastases showing a 71% overall response rate in an NCI-led investigator-sponsored trial. A separate Phase 2 study (NCT05286814) of PDS01ADC combined with HAIP FUDR showed a 77.8% 6-month ORR in mCRC liver-metastasis patients. The drug has also been studied in a Phase 1/2 trial for metastatic prostate cancer in combination with docetaxel. The company held a KOL event on October 15, 2026, to discuss the mCRC data and development path.

The Two-Sided Case

▲ Bull Case5
Phase 2 data showed a 71% overall response rate (ORR) in metastatic colorectal cancer patients with liver metastases, a population with very poor prognosis and high unmet need.
PDS0301 is a tumor-targeted immunocytokine (IL-12 antibody fusion) designed to concentrate IL-12 at the tumor site, potentially avoiding systemic toxicity while driving anti-tumor immunity.
Dr. Patrick Soon-Shiong (NantWorks/Nant Capital) led a $22.3M PIPE financing in September 2026 and joined the Board, signaling deep-pocketed strategic support and potential access to NantWorks' infrastructure.
Analyst consensus is strongly bullish: 8 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $4.50 (roughly 317% upside from the current $1.03).
Institutional accumulation is evident: Morgan Stanley doubled its position in Q2 2026, and UBS, Raymond James, and Susquehanna all added or doubled positions in Q2/Q3 2026.
▼ Bear Case5
PDS0301 is still in early-to-mid stage development (Phase 2), with no guarantee that the promising 71% ORR seen in small Phase 2 cohorts will replicate in larger, more rigorous trials.
The company discontinued its Phase 3 PDS0101 program and laid off its pipeline to focus on PDS0301, making it a single-asset company with no revenue and high execution risk.
PDSB stock crashed roughly 67% in August 2026 when the strategic refocus was announced, reflecting investor skepticism about abandoning a Phase 3 asset for a Phase 2 candidate.
The metastatic colorectal cancer space is highly competitive, with multiple approved therapies and emerging contenders like botensilimab (Agenus) and ivonescimab showing strong data.
The company has limited cash; the September 2026 PIPE of up to $22.3M provides runway but may not be sufficient to complete a pivotal trial without additional financing and dilution.

Upcoming Catalysts

  • Q3 2026 earnings call on November 12, 2026, where management may provide PDS0301 development updates and cash runway guidance
  • Potential End-of-Phase 2 FDA meeting to discuss registrational path for PDS0301 in mCRC with liver metastases
  • Additional Phase 2 data readouts from ongoing NCI-led trials in mCRC and potentially other indications

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PDS Biotechnology Corp 8-K PDSB ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 streetinsider.com3 pulse2.com4 fiercebiotech.com5 morningstar.com6 msn.com7 curetoday.com8 seekingalpha.com9 msn.com